Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Hepatocellular Carcinoma Clinical Trial

Official title:

An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01559844
• Other study ID #: P7977-2025
• Status: Completed
• Phase: Phase 2
• First received: March 5, 2012
• Last updated: June 2, 2015
• Start date: March 2012
• Est. completion date: October 2014

Study information

• Verified date: June 2015
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected subjects with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior to undergoing liver transplantation for up to 24 weeks can prevent post-transplant re-infection as determined by a sustained post-transplant virological response (HCV RNA < LLoQ) at 12 weeks post-transplant.

Participants will enroll in the pretransplant treatment phase (24 or 48 weeks). Participants enrolling for 24 weeks in the pretransplant treatment phase may receive treatment for up to an additional 24 weeks in the pretransplant retreatment phase. Participants enrolling for 48 weeks in the pretransplant treatment will have a second baseline at Week 24 for combined analysis in the pretransplant retreatment phase.

Participants who undergo liver transplant will stop all study drug 24 hours prior to transplant, and enter a 48-week follow-up phase to monitor for recurrent HCV infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: October 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent

2. Males or females, age > 18 years old

3. Males must agree to consistently and correctly use a condom while their female partner agrees to use an approved form of birth control from the date of screening until 7 months after their last dose of ribavirin.

4. Confirmation of chronic HCV infection documented by at least one measurement of serum HCV RNA above the LLOQ measured at screening, and at least one of the following:

• Positive anti-HCV antibody test, HCV RNA or HCV genotyping test at least 6 months prior to the baseline/Day 1 visit together with positive HCV RNA test and anti-HCV antibody at the time of screening, or

• Positive HCV RNA test and anti-HCV antibody test at the time of screening together with either a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed before enrollment with evidence of chronic HCV infection, such as the presence of fibrosis)

5. HCV RNA > 10^4 IU/mL at screening

6. Patients meeting the MILAN criteria undergoing liver transplant for HCC secondary to HCV with a MELD of < 22 and a HCC weighted MELD of = 22.

7. Child-Pugh Score (CPT) = 7

8. Planned management of the subject to meet United Network for Organ Sharing (UNOS) criteria, with imaging studies made available for review if required.

9. Has not been treated with any investigational drug or device within 30 days of the screening visit.

Exclusion Criteria:

1. Females of child-bearing potential who is pregnant or nursing

2. Prior exposure to a direct-acting antiviral targeting the HCV nonstructural (NS)5B polymerase

3. Any transplant patient who has agreed to a liver transplant from a live donor.

4. Participants requiring planned induction therapy with biologics posttransplantation or with a posttransplantation immunosuppressive regimen not consistent with the following within the first 12 weeks posttransplant:

• Solumedrol/Prednisone (tapering over approximately 7 days)

• Tacrolimus (maintaining a serum level of 5 12 ng/mL)

• Mycophenolate mofetil (up to 2 g/day)

• Introduction of new maintenance immunosuppressants different from the above list is disallowed except in consultation during the first 12 weeks posttransplant

5. Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome and hepatopulmonary syndrome, among other signs of decompensated cirrhosis.

6. Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, cholangitis)

7. Infection with hepatitis B virus (HBV) or HIV

8. Contraindications to RBV therapy

9. Chronic use of systemically administered immunosuppressive agents (eg, prednisone equivalent > 10 mg/day) in the pretransplant treatment period.

10. History of previous solid organ transplantation

11. Evidence of renal impairment (CLcr < 60 mL/min) calculated by the Cockcroft-Gault equation.

12. History or current evidence of psychiatric illness, immunologic disorder, hemoglobinopathy, pulmonary or cardiac disease, porphyria, or poorly controlled diabetes, cancer other than HCC, or a history of malignancy that in the opinion of the investigator makes the patient unsuitable for the study. Patients with clinical signs or symptoms of acute pancreatitis with elevated lipase (at Screening or during the screening period)

13. Known hypersensitivity to RBV, the study investigational medicinal product, the metabolites, or formulation excipients

14. History of having received any systemic antineoplastic (including sorafenib) or immunomodulatory treatment (including radiation) within 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study (excluding a local regional therapy such as TACE).

15. Treatment with Transcatheter arterial chemoembolization (TACE) or radio frequency ablation (RFA) within 30 days prior to the first dose.

16. Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to first dose administration at the baseline/Day 1 Visit.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatocellular Carcinoma

Intervention

Drug:
• Sofosbuvir
Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
• Ribavirin
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and = 75 kg = 1200 mg)

Locations

Country	Name	City	State
New Zealand	Auckland Clinical Studies	Auckland
Spain	Liver Unit Clinica University de Navara	Pamplona
United States	University of Colorado	Aurora	Colorado
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Lahey Clinic Medical Center	Burlington	Massachusetts
United States	Baylor Health Care System	Dallas	Texas
United States	Henry Ford Hospital	Detroit	Michigan
United States	UCLA Medical Center-The Pfleger Liver Institute	Los Angeles	California
United States	University of Miami	Miami	Florida
United States	Mount Sinai Medical Center	Miami Beach	Florida
United States	Columbia University	New York	New York
United States	Thomas Jefferson University Hospital	Philadelphia	Pennsylvania
United States	UC San Diego	San Diego	California
United States	University of California, San Francisco	San Francisco	California
United States	St. Louis University Hospital	St. Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Countries where clinical trial is conducted

United States,  New Zealand,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12	pTVR was defined as HCV RNA < the lower limit of quantification (LLOQ, ie, 25 mL/IU) at Week 12 after transplant.	Posttransplant Week 12	No
Primary	Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sobosbuvir Prior to Receiving Transplant		Up to 48 weeks prior to transplant	No
Primary	Percentage of Participants With Graft Loss Following Transplant		Up to 48 weeks following transplant	No
Primary	Number of Participants Who Died	Treatment-emergent deaths were those that occurred while taking study drug or within 30 days after stopping study drug.; Only those participants who underwent liver transplantation were analyzed for death post-transplantation.	Up to 48 weeks following transplant	No
Secondary	Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48	pTVR was defined as HCV RNA < the lower limit of quantification (LLOQ, ie, 25 mL/IU) at the relevant time point after transplant.	Up to 48 weeks following transplant	No
Secondary	Percentage of Participants With HCV RNA < LLOQ (ie, 25 mL/IU) During Treatment Through Week 48		Up to 48 weeks prior to transplant	No
Secondary	HCV RNA and Change From Baseline in HCV RNA Through Week 8		Up to 8 weeks prior to transplant	No
Secondary	Proportion of Participants With Virologic Failure Prior to Transplant	Virologic failure (VF) in the pretransplant phase was defined by: Breakthrough (HCV RNA = 25 IU/ml after having previously had HCV RNA < 25 IU/ml, while on treatment); Rebound (breakthrough or > 1 log10 IU/ml increase in HCV RNA from nadir while on treatment); Non-response (HCV RNA = 25 IU/ml through 8 weeks of treatment); Pre-transplant relapse (HCV RNA = 25 IU/ml during the Pre-Transplant off-treatment follow-up period after having achieved HCV RNA < 25 IU/ml at last observed HCV RNA on treatment)	Up to 48 weeks prior to transplant	No